|
US8986704B2
(en)
|
2012-07-06 |
2015-03-24 |
Valneva Austria Gmbh |
Mutant fragments of OspA and methods and uses relating thereto
|
|
US10947543B2
(en)
|
2013-03-13 |
2021-03-16 |
Yale University |
Interferon production using short RNA duplexes
|
|
US20180128545A1
(en)
|
2016-11-08 |
2018-05-10 |
Berry Metal Company |
Modular furnace cooling wall
|
|
WO2018189372A1
(en)
|
2017-04-13 |
2018-10-18 |
Valneva Austria Gmbh |
Multivalent ospa polypeptides and methods and uses relating thereto
|
|
CA3131096A1
(en)
|
2019-04-05 |
2020-10-08 |
Chi-Huey Wong |
Sialidase-resistant saccharide and method of making and using the same
|
|
US20210142868A1
(en)
|
2019-11-12 |
2021-05-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for identifying, classifying, and/or ranking genetic sequences
|
|
AU2021205866A1
(en)
*
|
2020-01-09 |
2022-09-08 |
The University Of Queensland |
Self-assembling, self-adjuvanting system for delivery of vaccines
|
|
HUE062777T2
(hu)
|
2020-02-26 |
2023-12-28 |
Vir Biotechnology Inc |
SARS-CoV-2 elleni antitestek
|
|
AU2021230334A1
(en)
*
|
2020-03-05 |
2022-09-29 |
New York Blood Center, Inc. |
Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
|
|
US11365239B2
(en)
*
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
WO2021190980A1
(en)
*
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
WO2021194965A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Centivax, Inc. |
Superhuman anti-sars-cov-2 antibodies and uses thereof
|
|
WO2021194985A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Centivax, Inc. |
Anti-sars-cov-2 antibodies derived from 6nb6
|
|
WO2021194886A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Centivax, Inc. |
Anti-sars-cov-2 antibodies derived from 3bgf
|
|
WO2021194891A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Centivax, Inc. |
Anti-sars-cov-2 antibodies derived from cr3022
|
|
WO2021194951A1
(en)
|
2020-03-23 |
2021-09-30 |
Centivax, Inc. |
Anti-sars-cov-2 antibodies derived from 2dd8
|
|
WO2021194896A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Centivax, Inc. |
Anti-sars-cov-2 antibodies derived from 2ghw
|
|
CN111349150B
(zh)
*
|
2020-03-24 |
2021-02-09 |
北京中科微盾生物科技有限责任公司 |
一种抑制新型冠状病毒的多肽及其用途
|
|
WO2021195418A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
|
CR20220552A
(es)
*
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
WO2021198999A1
(en)
*
|
2020-04-03 |
2021-10-07 |
Axon Neuroscience Se |
Epitope-based vaccines for treatment of coronavirus associated diseases
|
|
IL297166A
(en)
|
2020-04-09 |
2022-12-01 |
Valneva Austria Gmbh |
Compositions comprising three ospa fusion proteins for medical use
|
|
US20240026412A1
(en)
*
|
2020-04-09 |
2024-01-25 |
Valneva Austria Gmbh |
Improved methods of producing a lipidated protein
|
|
WO2021217062A1
(en)
*
|
2020-04-24 |
2021-10-28 |
Kevin Fialko |
Sars-cov-2 susceptibility detection
|
|
CN115461364B
(zh)
*
|
2020-04-28 |
2025-12-16 |
北京大学 |
一种抗新型冠状病毒的单克隆抗体及其应用
|
|
WO2021221136A1
(ja)
*
|
2020-05-01 |
2021-11-04 |
花王株式会社 |
抗ＳＡＲＳ－ＣｏＶ－２抗体
|
|
US20230357364A1
(en)
*
|
2020-05-06 |
2023-11-09 |
International Aids Vaccine Initiative, Inc. |
Covid-19 antibodies and uses thereof
|
|
US12584917B2
(en)
*
|
2020-05-06 |
2026-03-24 |
Academia Sinica |
Recombinant antibodies, kits comprising the same, and uses thereof
|
|
WO2021222988A1
(en)
*
|
2020-05-07 |
2021-11-11 |
Griffith University |
Cell entry-modulating agents and uses therefor
|
|
CA3182526A1
(en)
|
2020-05-08 |
2021-11-11 |
Academia Sinica |
Chimeric influenza vaccines
|
|
US11789020B2
(en)
*
|
2020-05-12 |
2023-10-17 |
Sapphire Biotech, Inc. |
Neutralizing antibody testing and treatment
|
|
MX2022014598A
(es)
*
|
2020-05-26 |
2023-03-31 |
Regeneron Pharma |
Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
|
|
CR20220660A
(es)
|
2020-06-03 |
2023-02-17 |
Regeneron Pharma |
Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
|
|
EP4176262B1
(en)
|
2020-07-02 |
2025-06-25 |
King Abdullah University Of Science And Technology |
Nanobody functionalized electrochemical transistors and methods of making and using thereof
|
|
US20240409617A1
(en)
*
|
2020-07-03 |
2024-12-12 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
|
CA3183367A1
(en)
|
2020-07-06 |
2022-01-13 |
Gevorg GRIGORYAN |
Antigen binding molecules targeting sars-cov-2
|
|
CA3183373A1
(en)
|
2020-07-06 |
2022-01-13 |
Gevorg GRIGORYAN |
Antigen binding molecules targeting sars-cov-2
|
|
EP4182687A4
(en)
*
|
2020-07-20 |
2024-09-11 |
Bio-Rad Laboratories, Inc. |
IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR
|
|
US20230295274A1
(en)
|
2020-07-27 |
2023-09-21 |
Single Cell Technology, Inc. |
Anti-sars coronavirus-2 spike protein antibodies
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
WO2022032139A1
(en)
*
|
2020-08-07 |
2022-02-10 |
Sorrento Therapeutics, Inc. |
Neutralizing antibodies that bind the sars-cov-2 s protein
|
|
CN111978378B
(zh)
*
|
2020-08-10 |
2022-02-01 |
武汉大学 |
SARS-CoV-2抗原多肽及其应用
|
|
US20220056111A1
(en)
*
|
2020-08-11 |
2022-02-24 |
Yurogen Biosystems Llc |
MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOF
|
|
US20230312689A1
(en)
*
|
2020-08-26 |
2023-10-05 |
National University Corporation Kumamoto University |
Human antibody or antigen-binding fragment thereof against coronavirus spike protein
|
|
KR20230058434A
(ko)
|
2020-08-26 |
2023-05-03 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
SARS-CoV-2를 표적으로 하는 항원 결합 분자
|
|
US20220074882A1
(en)
*
|
2020-09-04 |
2022-03-10 |
Fraunhofer Usa, Inc. |
Electrochemical-based sensor for rapid and direct detection of sars-cov-2
|
|
EP4211158A4
(en)
*
|
2020-09-14 |
2025-09-17 |
Nanjing Vazyme Biotech Co Ltd |
NEUTRALIZING ANTIBODIES AGAINST SARS-CoV-2
|
|
WO2022054068A1
(en)
*
|
2020-09-14 |
2022-03-17 |
Ramot At Tel-Aviv University Ltd. |
Antibodies for the prevention, treatment and detection of coronavirus infection
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
US20250188154A1
(en)
*
|
2020-09-15 |
2025-06-12 |
Duke University |
Coronavirus antibodies and uses thereof
|
|
TWI796597B
(zh)
*
|
2020-09-21 |
2023-03-21 |
長庚大學 |
使用紫蘇之經水萃取的產物來對抗冠狀病毒感染的方法
|
|
WO2022072654A1
(en)
*
|
2020-09-30 |
2022-04-07 |
The Research Foundation For The State University Of New York |
Particle based formulations of sars-cov-2 receptor binding domain
|
|
CN112125973B
(zh)
*
|
2020-09-30 |
2022-02-01 |
上海市公共卫生临床中心 |
冠状病毒的特异性抗体或其抗原结合片段
|
|
WO2022068844A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Vazyme Biotech Co., Ltd. |
Neutralizing antibody against sars-cov-2
|
|
CN116023478B
(zh)
*
|
2020-09-30 |
2025-10-10 |
超非凡(上海)医疗科技有限公司 |
冠状病毒的中和抗体或其抗原结合片段
|
|
CN112159469B
(zh)
*
|
2020-09-30 |
2022-08-02 |
上海市公共卫生临床中心 |
冠状病毒的抗体或其抗原结合片段
|
|
CN116419971A
(zh)
*
|
2020-09-30 |
2023-07-11 |
南京金斯瑞生物科技有限公司 |
抗SARS-CoV-2刺突蛋白膜外区的单克隆抗体及其应用
|
|
PE20231507A1
(es)
*
|
2020-10-02 |
2023-09-26 |
Lilly Co Eli |
Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
|
|
WO2022075921A1
(en)
*
|
2020-10-08 |
2022-04-14 |
Hummingbird Bioscience Holdings Limited |
Sars-cov-2 spike protein antigen-binding molecules
|
|
MX2023004023A
(es)
*
|
2020-10-09 |
2023-07-07 |
Hospital For Sick Children |
Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados.
|
|
CA3128660A1
(en)
*
|
2020-10-09 |
2022-04-09 |
Eric G. Marcusson |
Compositions and methods for the prevention and/or treatment of covid-19
|
|
WO2022079606A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Icosagen Cell Factory Oü |
Sars cov-2 neutralizing antibodies
|
|
CN112251414A
(zh)
*
|
2020-10-12 |
2021-01-22 |
中国科学院苏州纳米技术与纳米仿生研究所 |
一种杂交瘤细胞株、其制备方法和应用
|
|
US20230382978A1
(en)
*
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
|
CN112194711A
(zh)
*
|
2020-10-15 |
2021-01-08 |
深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） |
一种新型冠状病毒s蛋白的b细胞线性抗原表位、抗体、鉴定方法及应用
|
|
WO2022082217A1
(en)
|
2020-10-16 |
2022-04-21 |
Eureka Therapeutics, Inc. |
Compositions for preventing or treating viral and other microbial infections
|
|
WO2022084817A1
(en)
*
|
2020-10-19 |
2022-04-28 |
Lay Sciences Inc. |
Protein drugs for prevention and treatment of covid-19
|
|
GB202016650D0
(en)
*
|
2020-10-20 |
2020-12-02 |
Primer Design Ltd |
Kit and method
|
|
WO2022087127A1
(en)
*
|
2020-10-20 |
2022-04-28 |
Duke University |
Replication incompetent influenza vaccine platform for foreign protein delivery
|
|
US20230398204A1
(en)
*
|
2020-10-21 |
2023-12-14 |
La Jolla Institute For Immunology |
Coronavirus Spike Glycoprotein With Improved Expression and Stability
|
|
KR20220054080A
(ko)
*
|
2020-10-23 |
2022-05-02 |
주식회사 와이바이오로직스 |
SARS-CoV-2 스파이크 단백질에 특이적으로 결합하는 항체 및 이의 용도
|
|
CN112409488B
(zh)
*
|
2020-10-23 |
2022-07-01 |
中国科学院上海药物研究所 |
针对多种冠状病毒的单克隆抗体及应用
|
|
US20240025971A1
(en)
*
|
2020-10-23 |
2024-01-25 |
Atreca, Inc. |
Antibodies to coronavirus sars-cov-2
|
|
WO2022093745A1
(en)
*
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
WO2022093895A1
(en)
*
|
2020-10-27 |
2022-05-05 |
The University Of North Carolina At Chapel Hill |
Chimeric coronavirus s protein compositions and methods of use
|
|
AU2021369409A1
(en)
*
|
2020-10-30 |
2023-06-15 |
Adaptive Biotechnologies Corporation |
Anti-sars-cov-2 antigen antibodies and related compositions and methods
|
|
US11739137B2
(en)
*
|
2020-10-30 |
2023-08-29 |
The Government Of The United States Of America, As Represented By The Secretary Of The Navy |
Single domain antibodies to SARS-CoV-2 nucleocapsid protein
|
|
CN116848269A
(zh)
*
|
2020-10-30 |
2023-10-03 |
阿奇洛伊斯生物制药公司 |
多价颗粒组合物和使用方法
|
|
WO2022094011A1
(en)
*
|
2020-10-30 |
2022-05-05 |
Massachusetts Institute Of Technology |
Novel sars-cov-2 antigens and uses thereof
|
|
US11453705B2
(en)
|
2020-10-30 |
2022-09-27 |
Achelois Biopharma, Inc. |
Multivalent particles compositions and methods of use
|
|
CN112358533B
(zh)
*
|
2020-10-30 |
2023-07-14 |
上海泽润生物科技有限公司 |
重组刺突蛋白及其制备方法和用途
|
|
US20240059760A1
(en)
*
|
2020-11-02 |
2024-02-22 |
The University Of Chicago |
Polypeptides for detection and treatment of sars-cov-2
|
|
CN112098660B
(zh)
*
|
2020-11-03 |
2021-02-09 |
北京百普赛斯生物科技股份有限公司 |
新型冠状病毒中和性抗体检测试剂盒
|
|
IL302645A
(en)
*
|
2020-11-03 |
2023-07-01 |
The Wistrar Inst Of Anatomy And Biology |
Dna encoded nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine
|
|
US11919945B2
(en)
*
|
2020-11-04 |
2024-03-05 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
|
CN117098773A
(zh)
*
|
2020-11-06 |
2023-11-21 |
株式会社绿十字 |
特异于冠状病毒刺突蛋白的抗体及其用途
|
|
AU2021376384B2
(en)
*
|
2020-11-06 |
2026-04-16 |
Cho Pharma, Inc. |
Immune composition comprising antigen and glycoengineered antibody thereof
|
|
US20230417748A1
(en)
*
|
2020-11-06 |
2023-12-28 |
Green Cross Corporation |
Coronavirus Spike Protein-Specific Antibody and Use Thereof
|
|
WO2022095045A1
(zh)
*
|
2020-11-09 |
2022-05-12 |
上海济煜医药科技有限公司 |
SARS-CoV-2抗体及其应用
|
|
WO2022101839A1
(en)
*
|
2020-11-12 |
2022-05-19 |
Cadila Healthcare Limited |
Anti-sars-cov-2 monoclonal antibodies and cocktail thereof
|
|
JP7895943B2
(ja)
*
|
2020-11-12 |
2026-07-28 |
ティースキャン セラピューティクス インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用
|
|
WO2022102744A1
(ja)
*
|
2020-11-13 |
2022-05-19 |
株式会社ハカレル |
ＳＡＲＳ－ＣｏＶ－２のスパイクタンパク質に対する抗体
|
|
CN112625136B
(zh)
*
|
2020-11-18 |
2022-02-11 |
三优生物医药(上海)有限公司 |
针对冠状病毒具有中和活性的双特异性抗体及其用途
|
|
CN112409479B
(zh)
*
|
2020-11-23 |
2022-04-26 |
中国疾病预防控制中心病毒病预防控制所 |
人源抗新冠病毒中和性抗体nCoV-121及其应用
|
|
CA3200885A1
(en)
|
2020-11-23 |
2022-05-27 |
Genentech, Inc. |
Methods for modulating host cell surface interactions with sars-cov-2
|
|
US12704517B2
(en)
|
2020-11-24 |
2026-08-11 |
Bio-Techne Corporation |
Anti-severe acute respiratory syndrome coronavirus antibodies
|
|
JP2023550638A
(ja)
*
|
2020-11-25 |
2023-12-04 |
デシフェラ・ファーマシューティカルズ，エルエルシー |
ウイルス感染症の処置に使用するための、ｖｓｐ３４阻害剤としてのモルホリノ誘導体
|
|
CN117083064A
(zh)
*
|
2020-11-25 |
2023-11-17 |
德西费拉制药有限责任公司 |
作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物
|
|
CN112442120A
(zh)
*
|
2020-11-25 |
2021-03-05 |
苏州大学 |
抗严重急性呼吸系统综合征ii型冠状病毒sars-cov-2的中和抗体
|
|
CN112439058A
(zh)
*
|
2020-11-25 |
2021-03-05 |
深圳市第二人民医院(深圳市转化医学研究院) |
基于外泌体为载体的重组新型冠状病毒纳米疫苗方法
|
|
WO2022115558A1
(en)
*
|
2020-11-25 |
2022-06-02 |
Deciphera Pharmaceuticals, Llc |
Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection
|
|
WO2022112392A1
(en)
|
2020-11-26 |
2022-06-02 |
Memo Therapeutics Ag |
Anti-sars-cov-2 antibody molecules
|
|
MX2023006518A
(es)
|
2020-12-03 |
2023-06-23 |
Regeneron Pharma |
Metodos de identificacion de sujetos que tienen un mayor riesgo de desarrollar una infeccion por coronavirus y su tratamiento.
|
|
JP2024500313A
(ja)
*
|
2020-12-04 |
2024-01-09 |
ザ・ユニバーシティ・オブ・シカゴ |
コロナウイルス感染の検出および治療のためのポリペプチド
|
|
US20240044896A1
(en)
*
|
2020-12-09 |
2024-02-08 |
The University Of Chicago |
Methods and systems for detection and analysis of angiotensin binding antibodies
|
|
WO2022122788A1
(en)
*
|
2020-12-09 |
2022-06-16 |
Institute For Research In Biomedicine |
Multispecific antibodies against severe acute respiratory syndrome coronavirus 2
|
|
WO2022125789A1
(en)
*
|
2020-12-09 |
2022-06-16 |
Yale University |
Compositions and methods for treating, ameliorating, and/or preventing viral infections
|
|
US11693011B2
(en)
|
2020-12-14 |
2023-07-04 |
Inbios International, Inc. |
Neutralizing antibody immunoassays
|
|
WO2022132887A1
(en)
*
|
2020-12-15 |
2022-06-23 |
Board Of Regents, The University Of Texas System |
Human monoclonal antibodies targeting the sars-cov-2 spike protein
|
|
WO2022132904A1
(en)
*
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
TW202241942A
(zh)
*
|
2020-12-21 |
2022-11-01 |
日商中外製藥股份有限公司 |
Ｓａｒｓ－ｃｏｖ－２結合分子及其用途
|
|
KR102779353B1
(ko)
*
|
2020-12-22 |
2025-03-12 |
한국과학기술원 |
컴퓨터를 이용해 디자인된 SARS-CoV-2 수용체결합 도메인 특이적 항체 또는 그의 항원 결합 단편
|
|
WO2022133545A1
(en)
*
|
2020-12-23 |
2022-06-30 |
Garvan Institute Of Medical Research |
Sars-cov-2 antibodies
|
|
CN112794884B
(zh)
*
|
2020-12-28 |
2022-02-18 |
中国科学院微生物研究所 |
新型冠状病毒蛋白、制备方法及中和抗体检测试剂盒
|
|
CN112326973B
(zh)
*
|
2020-12-31 |
2021-03-23 |
北京金沃夫生物工程科技有限公司 |
一种用于检测新型冠状病毒抗体的试剂盒及其应用
|
|
US20240294613A1
(en)
*
|
2020-12-31 |
2024-09-05 |
The Broad Institute, Inc. |
Cross-neutralizing sars-cov2 antibodies
|
|
WO2022150809A1
(en)
*
|
2021-01-05 |
2022-07-14 |
Immunome, Inc. |
Antibody cocktail against sars-cov-2 spike protein
|
|
TW202241928A
(zh)
*
|
2021-01-08 |
2022-11-01 |
美商１０Ｘ基因組學有限公司 |
對冠狀病毒具有特異性的抗原結合多肽及其用途
|
|
US20240301037A1
(en)
*
|
2021-01-22 |
2024-09-12 |
La Jolla Institute For Immunology |
Chimeric anti-coronavirus spike protein antibodies
|
|
WO2022158497A1
(ja)
*
|
2021-01-22 |
2022-07-28 |
株式会社mAbProtein |
ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質に対する抗体
|
|
WO2022162587A1
(en)
*
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
CN113264998B
(zh)
*
|
2021-01-28 |
2023-02-28 |
四川大学华西医院 |
抗新冠病毒SARS-CoV-2表面S1蛋白的单链抗体及其应用
|
|
PY2204506A
(es)
*
|
2021-01-28 |
2022-08-30 |
Talem Therapeutics Llc |
Anticuerpos antiglicoproteína de espiga y su uso terapéutico
|
|
JP7598538B2
(ja)
*
|
2021-01-29 |
2024-12-12 |
東亞合成株式会社 |
ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
|
|
CN115109151B
(zh)
*
|
2021-01-31 |
2024-06-11 |
中南大学湘雅医院 |
新型冠状病毒单克隆抗体xy6及其应用
|
|
RU2771288C1
(ru)
*
|
2021-02-02 |
2022-04-29 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Штамм гибридных клеток животных Mus musculus 2E1B5 - продуцент моноклонального антитела к рецептор-связывающему домену белка S вируса SARS-CoV-2
|
|
US20240043507A1
(en)
*
|
2021-02-04 |
2024-02-08 |
Rq Biotechnology Limited |
Antibodies
|
|
AU2022221297A1
(en)
*
|
2021-02-09 |
2023-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
|
WO2022171904A1
(en)
|
2021-02-15 |
2022-08-18 |
Livingmed Biotech S.R.L. |
Genetically modified clostridium strains expressing recombinant antigens and uses thereof
|
|
WO2022182662A1
(en)
|
2021-02-23 |
2022-09-01 |
10X Genomics, Inc. |
Compositions and methods for mapping antigen-binding molecule affinity to antigen regions of interest
|
|
WO2022183185A1
(en)
*
|
2021-02-23 |
2022-09-01 |
Pandion Operations, Inc. |
Pd-1 antibodies, polypeptides and uses thereof
|
|
CN113009153B
(zh)
*
|
2021-02-25 |
2023-12-15 |
山东莱博生物科技有限公司 |
一种基于磁微粒化学发光的新冠病毒中和抗体检测试剂盒及其应用
|
|
WO2022183120A1
(en)
*
|
2021-02-26 |
2022-09-01 |
University Of Virginia Patent Foundation |
Development of covid-19 vaccine using a dual tlr ligand liposome adjuvant
|
|
US12024551B1
(en)
*
|
2021-03-04 |
2024-07-02 |
National Technology & Engineering Solutions Of Sandia, Llc |
Coronavirus neutralizing humanized antibodies and uses thereof
|
|
CA3177045A1
(en)
*
|
2021-03-15 |
2022-09-22 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for treating coronavirus infection
|
|
CN112679605B
(zh)
*
|
2021-03-15 |
2021-07-09 |
安源医药科技（上海）有限公司 |
针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用
|
|
EP4063384A1
(en)
*
|
2021-03-23 |
2022-09-28 |
Ceinge Biotecnologie Avanzate SCarl |
Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
|
|
CN113092776B
(zh)
*
|
2021-03-24 |
2024-12-10 |
苏州携创生物技术有限公司 |
一种SARS-CoV-2中和抗体检测试剂盒
|
|
EP4304651A2
(en)
*
|
2021-03-26 |
2024-01-17 |
Atreca, Inc. |
Antibodies to sars-cov-2
|
|
CN115141270A
(zh)
*
|
2021-03-29 |
2022-10-04 |
深圳市康麦生物技术有限公司 |
特异性结合新型冠状病毒的抗体
|
|
US20240307486A1
(en)
*
|
2021-03-30 |
2024-09-19 |
Baylor College Of Medicine |
Methods and compositions for high-potency polypeptide-based protein inhibition
|
|
WO2022210830A1
(ja)
*
|
2021-03-30 |
2022-10-06 |
国立大学法人 富山大学 |
抗ＳＡＲＳ－ＣｏＶ－２抗体
|
|
WO2022211558A1
(ko)
*
|
2021-04-01 |
2022-10-06 |
(주)셀트리온 |
사스-코로나바이러스-2 스파이크 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자
|
|
JP7750614B2
(ja)
*
|
2021-04-05 |
2025-10-07 |
エルジー・ケム・リミテッド |
コロナウイルスワクチン組成物
|
|
KR102846776B1
(ko)
*
|
2021-04-08 |
2025-08-14 |
한국생명공학연구원 |
제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방용 중화능 개량 백신 조성물
|
|
WO2022221837A2
(en)
|
2021-04-12 |
2022-10-20 |
Academia Sinica |
Improved coronavirus vaccine
|
|
US20240199725A1
(en)
*
|
2021-04-16 |
2024-06-20 |
Korea University Research And Business Foundation |
Human antibody targeting covid-19 virus
|
|
WO2022224271A1
(en)
*
|
2021-04-19 |
2022-10-27 |
Bharat Serums And Vaccines Limited |
Polyclonal antibodies against sars-cov-2 and implementations thereof
|
|
MX2023012530A
(es)
*
|
2021-04-20 |
2024-01-08 |
D4 Labs Llc |
Composición y metodos de vacuna adyuvada.
|
|
WO2022226079A1
(en)
*
|
2021-04-20 |
2022-10-27 |
Inbios International, Inc. |
Neutralizing antibodies against sars-cov-2
|
|
JP2024518335A
(ja)
*
|
2021-04-26 |
2024-05-01 |
アンスティチュ パスツール |
ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用
|
|
KR102426782B1
(ko)
*
|
2021-04-27 |
2022-07-28 |
국민대학교산학협력단 |
SARS-CoV-2 RBD 항원 특이적 항체를 포함하는 진단용 조성물 또는 키트
|
|
WO2022231320A1
(ko)
*
|
2021-04-27 |
2022-11-03 |
국민대학교산학협력단 |
Sars-cov-2 s 단백질에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편, 및 이들의 용도
|
|
BR112023022493A2
(pt)
*
|
2021-04-28 |
2024-02-15 |
Univ Columbia |
Anticorpos para tratamento e prevenção de covid-19 e variantes emergentes
|
|
WO2022235678A1
(en)
*
|
2021-05-03 |
2022-11-10 |
Ohio State Innovation Foundation |
Human anti-coronavirus peptide vaccines and methods of their use
|
|
WO2022235960A1
(en)
*
|
2021-05-06 |
2022-11-10 |
Sorrento Therapeutics, Inc. |
Neutralizing antibodies that bind variant sars-cov-2 spike proteins
|
|
US20240262893A1
(en)
*
|
2021-05-12 |
2024-08-08 |
Applied Biomedical Science Institute |
Binding polypeptides against sars cov-2 and uses thereof
|
|
CN112981011B
(zh)
*
|
2021-05-12 |
2021-08-17 |
广东凯普生物科技股份有限公司 |
一种检测SARS-CoV-2的引物组合物及其应用
|
|
EP4089112A1
(en)
*
|
2021-05-14 |
2022-11-16 |
Ustav organicke chemie a biochemie AV CR, v.v.i. |
Antibody binding to rbd of spike protein of sars-cov-2 and a method for quantifying protective antibodies against sars-cov-2
|
|
GB202107057D0
(en)
|
2021-05-18 |
2021-06-30 |
Univ York |
Glycosylation method
|
|
BR112023024034A2
(pt)
*
|
2021-05-20 |
2024-02-06 |
Mayo Found Medical Education & Res |
Polipeptídeos de sars-cov-2
|
|
WO2022251403A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Icahn School Of Medicine At Mount Sinai |
Sars-cov-2 antibodies and uses thereof
|
|
CN113354733B
(zh)
*
|
2021-06-04 |
2022-02-18 |
武汉生物制品研究所有限责任公司 |
一种抗SARS-CoV-2流行突变株的单克隆抗体20D8
|
|
CN117897173A
(zh)
*
|
2021-06-08 |
2024-04-16 |
伊莱利利公司 |
含有2019新型冠状病毒抗体的药物制剂
|
|
CN113416245A
(zh)
*
|
2021-06-15 |
2021-09-21 |
北京华大蛋白质研发中心有限公司 |
一种可结合SARS-CoV-2病毒RBD蛋白的中和抗体及其应用
|
|
WO2022263638A1
(en)
*
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
WO2022271884A2
(en)
*
|
2021-06-22 |
2022-12-29 |
Twist Bioscience Corporation |
Methods and compositions relating to covid antibody epitopes
|
|
US20250320278A1
(en)
*
|
2021-06-25 |
2025-10-16 |
La Jolla Institute For Immunology |
Chimeric anti-sars-cov2 nucleoprotein antibodies
|
|
WO2023275538A1
(en)
*
|
2021-06-28 |
2023-01-05 |
Diosynvax Ltd |
Beta-coronavirus vaccines
|
|
CN113584223B
(zh)
*
|
2021-06-28 |
2024-01-12 |
中国人民解放军疾病预防控制中心 |
基于CRISPR-Cas12a的SARS-CoV-2中D614G突变鉴定方法
|
|
CN115594758B
(zh)
*
|
2021-06-28 |
2026-05-05 |
中国科学院分子细胞科学卓越创新中心 |
抗新型冠状病毒SARS-CoV-2的纳米抗体及其制备方法和用途
|
|
AU2022307659A1
(en)
|
2021-07-05 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
|
EP4370210A1
(en)
*
|
2021-07-14 |
2024-05-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
WO2023285620A2
(en)
*
|
2021-07-14 |
2023-01-19 |
Alchemab Therapeutics Ltd. |
Compositions and methods for targeting viral proteins
|
|
WO2023002944A1
(ja)
*
|
2021-07-19 |
2023-01-26 |
公立大学法人福島県立医科大学 |
新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）およびＳＡＲＳコロナウイルス（ＳＡＲＳ－ＣｏＶ）に結合する抗体
|
|
GB202110391D0
(en)
|
2021-07-19 |
2021-09-01 |
Tissue Click Ltd |
A detection kit and methods of detection of infectious agents
|
|
CN113621651A
(zh)
*
|
2021-07-19 |
2021-11-09 |
南昌五元生物科技有限公司 |
一种基于s-tet蛋白表达系统的细胞合胞体病变模型及其制备方法
|
|
EP4373523A4
(en)
*
|
2021-07-23 |
2025-06-11 |
The Trustees Of Columbia University In The City Of New York |
Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use
|
|
WO2023008463A1
(ja)
*
|
2021-07-28 |
2023-02-02 |
株式会社イーベック |
ＳＡＲＳ－ＣｏＶ－２野生株および変異株に対する中和ヒト抗体およびその抗原結合性断片
|
|
US11724077B2
(en)
*
|
2021-07-28 |
2023-08-15 |
Subhash Dhawan |
Therapeutic swabs for treating upper respiratory infections
|
|
US20250066455A1
(en)
*
|
2021-07-30 |
2025-02-27 |
The University Of Melbourne |
Neutralising antibodies and uses thereof
|
|
CN113512113B
(zh)
*
|
2021-08-03 |
2024-07-05 |
浙江大学医学院附属第一医院 |
人源化广谱高中和活性抗新型冠状病毒单克隆抗体及应用
|
|
EP4380954A4
(en)
*
|
2021-08-04 |
2025-07-09 |
Univ California |
SARS-COV-2 PSEUDO-VIRAL PARTICLES
|
|
WO2023023183A2
(en)
*
|
2021-08-17 |
2023-02-23 |
Twist Bioscience Corporation |
Sars-cov-2 antibodies and related compositions and methods of use
|
|
US20250296985A1
(en)
*
|
2021-08-25 |
2025-09-25 |
Translational Health Science And Technology Institute |
Potently neutralizing novel human monoclonal antibodies against sars-cov-2 (covid-19)
|
|
US12600764B2
(en)
|
2021-08-27 |
2026-04-14 |
International Business Machines Corporation |
Antigen-binding proteins targeting coronavirus (COV) variants
|
|
US20240270828A1
(en)
*
|
2021-09-03 |
2024-08-15 |
The Uab Research Foundation |
Human neutralizing antibodies against sars-cov-2 spike s2 domain and uses thereof
|
|
KR20230038626A
(ko)
*
|
2021-09-06 |
2023-03-21 |
국민대학교산학협력단 |
SARS-CoV-2에 특이적으로 결합하는 이중특이적 항체
|
|
WO2023048656A2
(en)
*
|
2021-09-24 |
2023-03-30 |
Chulalongkorn University |
Human monoclonal antibodies against the receptor-binding domain of sars-cov-2 spike protein
|
|
TW202334429A
(zh)
|
2021-10-01 |
2023-09-01 |
中央研究院 |
Sars-cov-2棘蛋白特異性抗體及其用途
|
|
WO2023064717A2
(en)
*
|
2021-10-08 |
2023-04-20 |
Augmenta Bioworks, Inc. |
Antibodies for sars-cov-2 and uses thereof
|
|
WO2023064435A2
(en)
*
|
2021-10-15 |
2023-04-20 |
The Children's Medical Center Corporation |
Compositions and methods relating to sars-cov-2 neutralizing antibodies
|
|
US20240408194A1
(en)
*
|
2021-10-20 |
2024-12-12 |
Arizona Board Of Regents On Behalf Of Arizona State University |
DNA ORIGAMI SUBUNIT VACCINE FOR PREVENTION OF SARS-CoV-2 VARIANT INFECTION
|
|
US20250042976A1
(en)
*
|
2021-10-26 |
2025-02-06 |
Roche Diagnostics Operations, Inc. |
Monoclonal antibodies specific for sars-cov-2 rbd
|
|
WO2023081434A2
(en)
*
|
2021-11-07 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
|
WO2023084055A1
(en)
*
|
2021-11-12 |
2023-05-19 |
Rq Biotechnology Limited |
Compositions
|
|
US20250026814A1
(en)
*
|
2021-11-16 |
2025-01-23 |
The University Of Chicago |
Polypeptides for detection and treatment of coronavirus infection
|
|
JP2024542793A
(ja)
*
|
2021-12-01 |
2024-11-15 |
ウニヴェルズィテート ツー ケルン |
Ｓａｒｓ関連コロナウイルスに対する中和抗体
|
|
EP4190810A1
(en)
*
|
2021-12-01 |
2023-06-07 |
Universität zu Köln |
Neutralizing antibodies against sars-related coronavirus
|
|
CN113862286B
(zh)
*
|
2021-12-03 |
2022-03-04 |
艾棣维欣(苏州)生物制药有限公司 |
编码sars-cov-2病毒c.37突变株抗原的dna分子、dna疫苗及应用
|
|
WO2023104904A2
(en)
*
|
2021-12-08 |
2023-06-15 |
Genclis |
The sars-cov-2 and variants use two independent cell receptors to replicate
|
|
WO2023108936A1
(zh)
*
|
2021-12-14 |
2023-06-22 |
杭州安旭生物科技股份有限公司 |
一种可结合SARS-CoV-2病毒的中和抗体及其应用
|
|
WO2023113094A1
(ko)
*
|
2021-12-16 |
2023-06-22 |
주식회사 씨티씨백 |
면역원성이 증가된 코로나바이러스감염증-19 백신 조성물
|
|
WO2023122535A2
(en)
*
|
2021-12-20 |
2023-06-29 |
DNARx |
Nucleic acid expression using subcutaneous administration
|
|
US20230279080A1
(en)
*
|
2021-12-27 |
2023-09-07 |
Academia Sinica |
Antibody specific to spike protein of sars-cov-2 and uses thereof
|
|
MX2024008361A
(es)
|
2022-01-14 |
2024-09-10 |
Regeneron Pharma |
Derivados de verrucarina a y conjugados anticuerpo-fármaco de los mismos.
|
|
TWI868567B
(zh)
*
|
2022-01-26 |
2025-01-01 |
中央研究院 |
冠狀病毒之特異性抗體及其用途
|
|
KR20240137083A
(ko)
*
|
2022-01-28 |
2024-09-19 |
에베크 인코포레이티드 |
변이주 교차성을 갖는 항SARS-CoV-2 인간 중화 항체 및 그의 항원 결합성 단편
|
|
EP4476546A1
(en)
*
|
2022-02-11 |
2024-12-18 |
Attana AB |
Analytical method
|
|
WO2023156187A1
(en)
*
|
2022-02-16 |
2023-08-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
High affinity antibodies against the sars-cov-2 receptor binding domain
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
CN114231497B
(zh)
*
|
2022-02-24 |
2022-05-20 |
广州伯尼兹生物科技有限公司 |
一株表达SARS-CoV-2 S1蛋白单克隆抗体杂交瘤细胞系及中和活性抗体
|
|
WO2023178182A1
(en)
|
2022-03-16 |
2023-09-21 |
10X Genomics, Inc. |
Compositions and methods for detection and treatment of coronavirus infection
|
|
WO2023190852A1
(ja)
*
|
2022-03-31 |
2023-10-05 |
公立大学法人福島県立医科大学 |
新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）に結合する抗体
|
|
JP2025081789A
(ja)
*
|
2022-03-31 |
2025-05-28 |
公立大学法人福島県立医科大学 |
新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）に結合する抗体
|
|
EP4508077A4
(en)
|
2022-04-14 |
2026-03-25 |
Invisishield Tech Ltd |
COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
|
|
CA3256035A1
(en)
|
2022-04-14 |
2023-10-19 |
Invisishield Technologies Ltd. |
COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
|
|
IL316848A
(en)
|
2022-05-06 |
2025-01-01 |
Generate Biomedicines Inc |
Antigen-binding molecules targeting SARS-CoV-2
|
|
CN115287265B
(zh)
*
|
2022-07-12 |
2023-05-23 |
四川大学华西医院 |
多能活性制剂诱发恒河猴抵抗新冠突变体的免疫防治模型
|
|
CN117659181A
(zh)
*
|
2022-09-06 |
2024-03-08 |
南特细胞公司 |
针对sars-cov-2刺突蛋白的肽治疗剂
|
|
EP4335870A1
(en)
*
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
EP4349860A1
(en)
|
2022-10-06 |
2024-04-10 |
Fundació Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM) |
Anti-sars-cov-2 antibodies
|
|
TW202426045A
(zh)
*
|
2022-10-07 |
2024-07-01 |
高端疫苗生物製劑股份有限公司 |
抗新型冠狀病毒(SARS-CoV-2) Omicron變異株之免疫組合物
|
|
KR102879761B1
(ko)
*
|
2022-12-13 |
2025-11-07 |
대한민국 |
코로나바이러스감염증-19 예방 또는 치료용 백신 조성물
|
|
US12589146B2
(en)
|
2023-02-22 |
2026-03-31 |
D4 Labs, Llc |
Adjuvanted protein vaccines comprising modified full-length spike protein of SARS-CoV-2 composition and methods of use
|
|
CN121057744A
(zh)
|
2023-02-28 |
2025-12-02 |
再生元制药公司 |
多价抗刺突蛋白结合分子及其用途
|
|
EP4673462A2
(en)
|
2023-02-28 |
2026-01-07 |
Regeneron Pharmaceuticals, Inc. |
Multivalent anti-spike protein binding molecules and uses thereof
|
|
WO2024211317A2
(en)
*
|
2023-04-07 |
2024-10-10 |
Icahn School Of Medicine At Mount Sinai |
Monoclonal antibodies to cadherin 11 and methods of use
|
|
NZ825394A
(en)
|
2023-04-08 |
2026-03-27 |
Rock Biomedical Inc |
Methods and compositions for dendritic cell targeting nano-delivery
|
|
CA3268566A1
(en)
|
2023-04-08 |
2024-10-17 |
Rock Biomedical Inc. |
METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
|
|
CN121175414A
(zh)
|
2023-05-17 |
2025-12-19 |
磐石医药生技股份有限公司 |
Mgat1缺乏细胞及其用途
|
|
CN121646605A
(zh)
|
2023-06-11 |
2026-03-10 |
再生元制药公司 |
环化抗体分子
|
|
WO2024258866A1
(en)
*
|
2023-06-12 |
2024-12-19 |
Interius Biotherapeutics, Inc. |
Compositions and methods for the treatment of immunological disorders
|
|
CN117379399A
(zh)
*
|
2023-06-27 |
2024-01-12 |
江生(深圳)生物技术研发中心有限公司 |
马源免疫球蛋白吸入液体制剂及其制备和使用方法
|
|
WO2025064752A1
(en)
*
|
2023-09-20 |
2025-03-27 |
La Jolla Institute For Immunology |
Human anti-sars-cov-2 spike (s) antibodies
|
|
TW202606662A
(zh)
|
2024-04-26 |
2026-02-16 |
美商美國禮來大藥廠 |
蛋白質酪胺酸激酶7抗體及抗體藥物結合物
|